Measurement of isoagglutinins in immunoglobulins for intravenous application by flow cytometry.


Journal

Analytical biochemistry
ISSN: 1096-0309
Titre abrégé: Anal Biochem
Pays: United States
ID NLM: 0370535

Informations de publication

Date de publication:
15 02 2020
Historique:
received: 19 08 2019
revised: 21 11 2019
accepted: 05 12 2019
pubmed: 11 12 2019
medline: 20 11 2020
entrez: 11 12 2019
Statut: ppublish

Résumé

Isoagglutinins present in intravenous immunoglobulin (IVIG) products have been linked to haemolysis. Therefore, accurately assessing isoagglutinin content in IVIG products is important. The standard European Pharmacopoeia (Ph.Eur.) direct assay is limited by low precision. Here, we describe the development of a fluorescence-activated cell sorting (FACS) method for assessing isoagglutinin levels. Serially diluted IVIG samples were incubated with red blood cells (RBCs), RBC-bound anti-A and anti-B antibodies were detected using a fluorescently-labelled antibody and the median fluorescence intensity of samples was assessed by FACS. Results were compared with the Ph.Eur. direct assay. The method was used to determine isoagglutinins in commercial products produced with and without isoagglutinin reduction steps. Assay precision, reported as the coefficient of variation, for the FACS method was 14% and 8% for anti-A and anti-B, respectively versus 33% and 20% with the Ph.Eur. direct assay. Application of the method on commercially available IVIGs revealed differences in isoagglutinin content between products produced with and without isoagglutinin reduction steps. This FACS assay allows for quantification of isoagglutinin concentrations in IVIGs with higher precision than the Ph.Eur. direct assay. Also the FACS assay confirms differences in isoagglutinin levels between IVIG products and the efficacy of isoagglutinin reduction measures.

Identifiants

pubmed: 31821802
pii: S0003-2697(19)30774-2
doi: 10.1016/j.ab.2019.113534
pii:
doi:

Substances chimiques

Hemagglutinins 0
Immunoglobulins, Intravenous 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

113534

Informations de copyright

Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest All authors are currently, or were previously, employed by CSL Behring, the funders of this research. In addition, Alphonse Hubsch and Dominik Stadler own shares of CSL. There are no further conflicts of interest to report.

Auteurs

Marc Bürzle (M)

CSL Behring AG, Wankdorfstrasse 10, 3014, Bern, Switzerland. Electronic address: marcbuerzle@gmx.li.

Alphonse Hubsch (A)

CSL Behring AG, Wankdorfstrasse 10, 3014, Bern, Switzerland.

Nicole Spiegl (N)

CSL Behring AG, Wankdorfstrasse 10, 3014, Bern, Switzerland.

Thomas Roten (T)

CSL Behring AG, Wankdorfstrasse 10, 3014, Bern, Switzerland.

Adriano Marques (A)

CSL Behring AG, Wankdorfstrasse 10, 3014, Bern, Switzerland.

Lukas Martig (L)

CSL Behring AG, Wankdorfstrasse 10, 3014, Bern, Switzerland.

Amgad Shebl (A)

CSL Behring AG, Wankdorfstrasse 10, 3014, Bern, Switzerland.

Dominik Stadler (D)

CSL Behring AG, Wankdorfstrasse 10, 3014, Bern, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH